| 1 |
Meunier-Carmenate Y, Valdés-García G, Maya-Martinez R, French-Pacheco L, Fernández-Silva A, González-Onofre Y, Millan-Pacheco C, Pastor N, Amero C. Unfolding and Aggregation Pathways of Variable Domains from Immunoglobulin Light Chains. Biochemistry 2023;62:1000-11. [PMID: 36802343 DOI: 10.1021/acs.biochem.2c00704] [Reference Citation Analysis]
|
| 2 |
Absmeier RM, Rottenaicher GJ, Svilenov HL, Kazman P, Buchner J. Antibodies gone bad - the molecular mechanism of light chain amyloidosis. FEBS J 2023;290:1398-419. [PMID: 35122394 DOI: 10.1111/febs.16390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 3 |
Goldis R, Kaplan B, Kukuy OL, Arad M, Magen H, Shavit-Stein E, Dori A, Livneh A. Diagnostic Challenges and Solutions in Systemic Amyloidosis. Int J Mol Sci 2023;24. [PMID: 36902083 DOI: 10.3390/ijms24054655] [Reference Citation Analysis]
|
| 4 |
Picken MM. Current Understanding of Systemic Amyloidosis and Underlying Disease Mechanisms. Am J Cardiol 2022;185 Suppl 1:S2-S10. [PMID: 36549788 DOI: 10.1016/j.amjcard.2022.10.057] [Reference Citation Analysis]
|
| 5 |
Martinez-rivas G, Bender S, Sirac C. Understanding AL amyloidosis with a little help from in vivo models. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1008449] [Reference Citation Analysis]
|
| 6 |
Takahashi D, Matsunaga E, Yamashita T, Caaveiro JM, Abe Y, Ueda T. Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vλ6 proteins associated with AL amyloidosis. Biochemical and Biophysical Research Communications 2022;596:22-8. [DOI: 10.1016/j.bbrc.2022.01.066] [Reference Citation Analysis]
|
| 7 |
Chang YT, Tsai WC, Lin WZ, Wu CC, Yu JC, Tseng VS, Liao GS, Hu JM, Hsu HM, Chang YJ, Lin MC, Chu CM, Yang CY. A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer. Front Oncol 2021;11:759952. [PMID: 35155184 DOI: 10.3389/fonc.2021.759952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Lavatelli F. Mechanisms of Organ Damage and Novel Treatment Targets in AL Amyloidosis. Hemato 2022;3:47-62. [DOI: 10.3390/hemato3010005] [Reference Citation Analysis]
|
| 9 |
Lewkowicz E, Gursky O. Dynamic protein structures in normal function and pathologic misfolding in systemic amyloidosis. Biophys Chem 2022;280:106699. [PMID: 34773861 DOI: 10.1016/j.bpc.2021.106699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 10 |
Gatt ME, Pick M. Learning from Patients: The Interplay between Clinical and Laboratory Research in AL Amyloidosis. Hemato 2021;3:3-16. [DOI: 10.3390/hemato3010002] [Reference Citation Analysis]
|
| 11 |
Peterle D, Klimtchuk ES, Wales TE, Georgescauld F, Connors LH, Engen JR, Gursky O. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation. J Mol Biol 2021;433:167310. [PMID: 34678302 DOI: 10.1016/j.jmb.2021.167310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Radamaker L, Karimi-Farsijani S, Andreotti G, Baur J, Neumann M, Schreiner S, Berghaus N, Motika R, Haupt C, Walther P, Schmidt V, Huhn S, Hegenbart U, Schönland SO, Wiese S, Read C, Schmidt M, Fändrich M. Role of mutations and post-translational modifications in systemic AL amyloidosis studied by cryo-EM. Nat Commun 2021;12:6434. [PMID: 34741031 DOI: 10.1038/s41467-021-26553-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 13 |
Roterman I, Stapor K, Fabian P, Konieczny L. In Silico Modeling of the Influence of Environment on Amyloid Folding Using FOD-M Model. Int J Mol Sci 2021;22:10587. [PMID: 34638925 DOI: 10.3390/ijms221910587] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 14 |
Yan W, Cao Y, Liao A, Yang W, Li J, Wang H. A prognostic staging system for light-chain amyloidosis using hepatic and renal indicator data from 1,064 Chinese patients. Ann Transl Med 2021;9:1347. [PMID: 34532484 DOI: 10.21037/atm-21-4033] [Reference Citation Analysis]
|
| 15 |
Rognoni P, Mazzini G, Caminito S, Palladini G, Lavatelli F. Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics. Medicina (Kaunas) 2021;57:916. [PMID: 34577839 DOI: 10.3390/medicina57090916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Haupt C. The AL Amyloid Fibril: Looking for a Link between Fibril Formation and Structure. Hemato 2021;2:505-514. [DOI: 10.3390/hemato2030032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Hemminki K, Försti A. Epidemiology of Amyloidosis and Genetic Pathways to Diagnosis and Typing. Hemato 2021;2:429-440. [DOI: 10.3390/hemato2030027] [Reference Citation Analysis]
|
| 18 |
Saunders CN, Chattopadhyay S, Huhn S, Weinhold N, Hoffmann P, Nöthen MM, Jöckel KH, Schmidt B, Landi S, Goldschmidt H, Milani P, Merlini G, Rowcieno D, Hawkins P, Hegenbart U, Palladini G, Wechalekar A, Schönland SO, Försti A, Houlston R, Hemminki K. Search for AL amyloidosis risk factors using Mendelian randomization. Blood Adv 2021;5:2725-31. [PMID: 34228109 DOI: 10.1182/bloodadvances.2021004423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 19 |
Sen MK, Almuslehi MSM, Shortland PJ, Mahns DA, Coorssen JR. Proteomics of Multiple Sclerosis: Inherent Issues in Defining the Pathoetiology and Identifying (Early) Biomarkers. Int J Mol Sci 2021;22:7377. [PMID: 34298997 DOI: 10.3390/ijms22147377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 20 |
Schönfelder J, Pfeiffer PB, Pradhan T, Bijzet J, Hazenberg BP, Schönland SO, Hegenbart U, Reif B, Haupt C, Fändrich M. Protease Resistance of ex vivo Amyloid Fibrils implies the proteolytic Selection of disease-associated Fibril Morphologies.. [DOI: 10.1101/2021.07.05.451219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Rius B, Mesgarzadeh JS, Romine IC, Paxman RJ, Kelly JW, Wiseman RL. Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Adv 2021;5:1037-49. [PMID: 33599742 DOI: 10.1182/bloodadvances.2020002813] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 22 |
Lin XY, Pan D, Sang LX, Chang B. Primary localized gastric amyloidosis: A scoping review of the literature from clinical presentations to prognosis . World J Gastroenterol 2021; 27(12): 1132-1148 [PMID: 33828390 DOI: 10.3748/wjg.v27.i12.1132] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 23 |
Radamaker L, Baur J, Huhn S, Haupt C, Hegenbart U, Schönland S, Bansal A, Schmidt M, Fändrich M. Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. Nat Commun 2021;12:875. [PMID: 33558536 DOI: 10.1038/s41467-021-21126-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 24 |
Rottenaicher GJ, Weber B, Rührnößl F, Kazman P, Absmeier RM, Hitzenberger M, Zacharias M, Buchner J. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains. J Biol Chem 2021;296:100334. [PMID: 33508322 DOI: 10.1016/j.jbc.2021.100334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 25 |
Stepanenko OV, Sulatsky MI, Mikhailova EV, Stepanenko OV, Povarova OI, Kuznetsova IM, Turoverov KK, Sulatskaya AI. Alpha-B-Crystallin Effect on Mature Amyloid Fibrils: Different Degradation Mechanisms and Changes in Cytotoxicity. Int J Mol Sci 2020;21:E7659. [PMID: 33081200 DOI: 10.3390/ijms21207659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Herrera GA, Teng J, Turbat-Herrera EA, Zeng C, Del Pozo-Yauner L. Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease. Kidney Int Rep 2020;5:1870-93. [PMID: 33163710 DOI: 10.1016/j.ekir.2020.07.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 27 |
Matsumura H, Furukawa Y, Nakagaki T, Furutani C, Osanai S, Noguchi K, Odaka M, Yohda M, Ohtani H, Michishita Y, Kawabata Y, Kitabayashi A, Ikeda S, Nara M, Komatsuda A, Takahashi N, Wakui H. Multiple Myeloma-Associated Ig Light Chain Crystalline Cast Nephropathy. Kidney Int Rep 2020;5:1595-602. [PMID: 32954087 DOI: 10.1016/j.ekir.2020.06.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 28 |
Menè P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro A. Monoclonal Gammopathies of Renal Significance: Renal Biopsy and Beyond. Cancers (Basel) 2020;12:E1741. [PMID: 32629844 DOI: 10.3390/cancers12071741] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 29 |
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S. CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond. Int J Mol Sci 2020;21:E4129. [PMID: 32531894 DOI: 10.3390/ijms21114129] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 30 |
Fenoglio R, Baldovino S, Ferro M, Sciascia S, Rabajoli G, Quattrocchio G, Beltrame G, Naretto C, Rossi D, Alpa M, Barreca A, Papotti MG, Roccatello D. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation. J Nephrol 2021;34:231-40. [PMID: 32472525 DOI: 10.1007/s40620-020-00748-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 31 |
Rius B, Mesgarzadeh JS, Romine IC, Paxman RJ, Kelly JW, Wiseman RL. ER Proteostasis Regulators Reduce Amyloidogenic Light Chain Secretion Through an On-Target, ATF6-Independent Mechanism.. [DOI: 10.1101/2020.05.15.098145] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 32 |
Pelaez-Aguilar AE, Valdés-García G, French-Pacheco L, Pastor N, Amero C, Rivillas-Acevedo L. Site-Specific Interactions with Copper Promote Amyloid Fibril Formation for λ6aJL2-R24G. ACS Omega 2020;5:7085-95. [PMID: 32280849 DOI: 10.1021/acsomega.9b03220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 33 |
Gerasimova EM, Fedotov SA, Kachkin DV, Vashukova ES, Glotov AS, Chernoff YO, Rubel AA. Protein Misfolding during Pregnancy: New Approaches to Preeclampsia Diagnostics. Int J Mol Sci 2019;20:E6183. [PMID: 31817906 DOI: 10.3390/ijms20246183] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 34 |
Maya-Martinez R, French-Pacheco L, Valdés-García G, Pastor N, Amero C. Different Dynamics in 6aJL2 Proteins Associated with AL Amyloidosis, a Conformational Disease. Int J Mol Sci 2019;20:E4078. [PMID: 31438515 DOI: 10.3390/ijms20174078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 35 |
Radamaker L, Lin YH, Annamalai K, Huhn S, Hegenbart U, Schönland SO, Fritz G, Schmidt M, Fändrich M. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis. Nat Commun 2019;10:1103. [PMID: 30894526 DOI: 10.1038/s41467-019-09032-0] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 36 |
Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. Nat Commun 2019;10:1269. [PMID: 30894521 DOI: 10.1038/s41467-019-09133-w] [Cited by in Crossref: 78] [Cited by in F6Publishing: 81] [Article Influence: 19.5] [Reference Citation Analysis]
|
| 37 |
Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain (AL) amyloidosis patient.. [DOI: 10.1101/444901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
